Please wait

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-3 No. 333-271359) of ARS Pharmaceuticals, Inc.;

 

(2)

Registration Statement (Form S-8 No. 333-269262) pertaining to the 2018 Equity Incentive Plan, the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc.;

 

(3)

Registration Statement (Form S-8 No. 333-261980) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.);

 

(4)

Registration Statement (Form S-8 No. 333-254827) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.);

(5)

Registration Statement (Form S-8 No. 333-251143) pertaining to the 2016 Equity Incentive Plan, the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.);

(6)

Registration Statement (Form S-3ASR No. 333-284650) of ARS Pharmaceuticals, Inc.;

 

(7)

Registration Statement (Form S-8 No. 333-278150) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.); and

 

(8)

Registration Statement (Form S-8 No. 333-285955) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.),

 

of our report dated March 9, 2026, with respect to the consolidated financial statements of ARS Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of ARS Pharmaceuticals, Inc. for the year ended December 31, 2025.

 

/s/ Ernst & Young LLP

 

San Diego, California

March 9, 2026